{"transactions":[{"id":727416,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":281162,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Medicxi Secondary Co-Invest I LP, a Jersey limited partnership (\"Medicxi Secondary Co-Invest I\").  MSI GP is the sole managing general partner of Medicxi Secondary Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Secondary Co-Invest I.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Secondary Co-Invest I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":727415,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11197303,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Held by Medicxi Secondary I LP, a Jersey limited partnership (\"Medicxi Secondary I\"). Medicxi Secondary I GP Limited, a Jersey limited liability company (\"MSI GP\"), is the sole managing general partner of Medicxi Secondary I, and Medicxi Manager is the sole manager of Medicxi Secondary I. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Secondary I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":727414,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93526,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":727413,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3936970,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":727412,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55677,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held by Medicxi Co-Invest I LP, a Jersey limited partnership (\"Medicxi Co-Invest I\"). MVI GP is the sole managing general partner of Medicxi Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Co-Invest I. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Co-Invest I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":727411,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:12.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4398519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by Medicxi Ventures I LP, a Jersey limited partnership (\"Medicxi Ventures I\"). Medicxi Ventures I GP Limited, a Jersey limited liability company (\"MVI GP\"), is the sole managing general partner of Medicxi Ventures I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\"), is the sole manager of Medicxi Ventures I. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Ventures I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000615","document":"wk-form4_1782332169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000147083126000615/wk-form4_1782332169.xml","form_type":"4"}},{"id":2319748,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-03-23T20:36:39.000Z","date":"2022-03-21","kind":"other","acquired":true,"shares":45054,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents ADSs received by Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP, for no consideration, pursuant to contingent value rights granted to Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP in January 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents ADSs received by Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP, for no consideration, pursuant to contingent value rights granted to Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP in January 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Secondary Co-Invest I LP, a Jersey limited partnership (\"Medicxi Secondary Co-Invest I\").  MSI GP is the sole managing general partner of Medicxi Secondary Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Secondary Co-Invest I.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Secondary Co-Invest I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":281162,"source":{"system":"sec-edgar","filing":"0000899243-22-011941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924322011941/doc4.xml","form_type":"4"}},{"id":2319747,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-03-23T20:36:39.000Z","date":"2022-03-21","kind":"other","acquired":true,"shares":1794211,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents ADSs received by Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP, for no consideration, pursuant to contingent value rights granted to Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP in January 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents ADSs received by Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP, for no consideration, pursuant to contingent value rights granted to Medicxi Secondary I LP and Medicxi Secondary Co-Invest I LP in January 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Secondary I LP, a Jersey limited partnership (\"Medicxi Secondary I\").  Medicxi Secondary I GP Limited, a Jersey limited liability company (\"MSI GP\"), is the sole managing general partner of Medicxi Secondary I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Secondary I.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Secondary I, except to the extent of his respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":11197303,"source":{"system":"sec-edgar","filing":"0000899243-22-011941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924322011941/doc4.xml","form_type":"4"}},{"id":2483427,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-06T22:31:11.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":796,"price":12.82,"value":10204.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":93526,"source":{"system":"sec-edgar","filing":"0000899243-21-046972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046972/doc4.xml","form_type":"4"}},{"id":2483426,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-06T22:31:11.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":33530,"price":12.82,"value":429854.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Growth I.  The Reporting Person is a member of the board of directors of Medicxi Manager.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3936970,"source":{"system":"sec-edgar","filing":"0000899243-21-046972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046972/doc4.xml","form_type":"4"}},{"id":2488101,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-02T22:24:07.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":1399,"price":12.62,"value":17655.38,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":92730,"source":{"system":"sec-edgar","filing":"0000899243-21-046599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046599/doc4.xml","form_type":"4"}},{"id":2488100,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-02T22:24:07.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":58905,"price":12.62,"value":743381.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Growth I.  The Reporting Person is a member of the board of directors of Medicxi Manager.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3903440,"source":{"system":"sec-edgar","filing":"0000899243-21-046599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046599/doc4.xml","form_type":"4"}},{"id":2488099,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-02T22:24:07.000Z","date":"2021-11-30","kind":"purchase","acquired":true,"shares":855,"price":11.62,"value":9935.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":91331,"source":{"system":"sec-edgar","filing":"0000899243-21-046599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046599/doc4.xml","form_type":"4"}},{"id":2488098,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-02T22:24:07.000Z","date":"2021-11-30","kind":"purchase","acquired":true,"shares":35992,"price":11.62,"value":418227.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Growth I.  The Reporting Person is a member of the board of directors of Medicxi Manager.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3844535,"source":{"system":"sec-edgar","filing":"0000899243-21-046599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046599/doc4.xml","form_type":"4"}},{"id":2491825,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-11-30T22:26:17.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":1315,"price":11.7003,"value":15385.8945,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":90476,"source":{"system":"sec-edgar","filing":"0000899243-21-046320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046320/doc4.xml","form_type":"4"}},{"id":2491824,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-11-30T22:26:17.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":55391,"price":11.7003,"value":648091.3173,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Growth I.  The Reporting Person is a member of the board of directors of Medicxi Manager.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3808543,"source":{"system":"sec-edgar","filing":"0000899243-21-046320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046320/doc4.xml","form_type":"4"}},{"id":2491823,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-11-30T22:26:17.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":274,"price":11.3353,"value":3105.8722,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":89161,"source":{"system":"sec-edgar","filing":"0000899243-21-046320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046320/doc4.xml","form_type":"4"}},{"id":2491822,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-11-30T22:26:17.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":11543,"price":11.3353,"value":130843.3679,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Growth I.  The Reporting Person is a member of the board of directors of Medicxi Manager.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3753152,"source":{"system":"sec-edgar","filing":"0000899243-21-046320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321046320/doc4.xml","form_type":"4"}},{"id":2680437,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"exercise","acquired":false,"shares":44828,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":44828},"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680436,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"exercise","acquired":false,"shares":1886990,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1886990},"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680435,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":44828,"price":11,"value":493108.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F9","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":44828,"derivative":{"underlying":"Ordinary Shares","underlying_shares":44828},"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680434,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1886990,"price":11,"value":20756890.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F9","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Share Split\"). This amount has been adjusted to give effect to the Share Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":1886990,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1886990},"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680433,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"purchase","acquired":true,"shares":13923,"price":20,"value":278460.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":88887,"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680432,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"purchase","acquired":true,"shares":586077,"price":20,"value":11721540.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3741609,"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680431,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"exercise","acquired":true,"shares":44828,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":74964,"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":2680430,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-04T21:01:01.000Z","date":"2021-06-02","kind":"exercise","acquired":true,"shares":1886990,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Person is a member of the board of directors of Medicxi Manager. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":3155532,"source":{"system":"sec-edgar","filing":"0000899243-21-022071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601521/000089924321022071/doc4.xml","form_type":"4"}},{"id":4521799,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant Shares","published_at":"2016-12-14T19:22:20.000Z","date":"2016-12-12","kind":"other","acquired":false,"shares":202634,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Composed of 35,376 warrant shares exercised by Index Ventures III (Jersey), L.P., 71,862 warrant shares exercised by Index Ventures III (Delaware), L.P., 1,280 warrant shares exercised by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 48,790 warrant shares exercised by Index Ventures IV (Jersey), L.P., 4,631 warrant shares exercised by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 38,584 warrant shares exercised by Index Ventures V (Jersey), L.P., 313 warrant shares exercised by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 1,798 warrant shares exercised by Yucca (Jersey) SLP."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Composed of 35,376 common shares acquired by Index Ventures III (Jersey), L.P., 71,862 common shares acquired by Index Ventures III (Delaware), L.P., 1,280 common shares acquired by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 48,790 common shares acquired by Index Ventures IV (Jersey), L.P., 4,631 common shares acquired by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 38,584 common shares acquired by Index Ventures V (Jersey), L.P., 313 common shares acquired by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 1,798 common shares acquired by Yucca (Jersey) SLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Index Venture Associates III Limited is the general partner of Index Ventures III (Jersey), L.P., Index Ventures III (Delaware), L.P., and Index Ventures III Parallel Entrepreneur Fund (Jersey)L.P. Yucca (Jersey) SLP is the Administrator of the Index Co-Investment Scheme acting through Elian Employee Benefit Services Limited. Index Venture Associates IV Limited is the general partner of Index Ventures IV (Jersey) L.P. and Index Ventures IV Parallel Entrepreneur Fund (Jersey) L.P. Index Venture Associates V Limited is the general partner of Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P. and Index Ventures V (Jersey), L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Composed of 813,095 common shares held by Index Ventures III (Jersey), L.P., 1,651,714 common shares held by Index Ventures III (Delaware), L.P., 29,424 common shares held by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 1,129,474 common shares held by Index Ventures IV (Jersey), L.P., 107,210 common shares held by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 893,199 common shares held by Index Ventures V (Jersey), L.P., 7,238 common shares held by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 59,552 common shares held by Yucca (Jersey) SLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Michele Ollier, Director of the Issuer, is a partner of Medicxi Ventures (Jersey) Limited Succursale de Geneve which provides sub-advisory services to the foregoing funds and Dr. Ollier disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interest therein. Francesco De Rubertis, Director of the Issuer, is a partner of Medicxi Ventures (UK) LLP which provides sub-advisory services to the foregoing funds and Dr. De Rubertis disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein. Index Venture Associates III Limited, Index Venture Associates IV Limited, Index Venture Associates V Limited and Yucca (Jersey) SLP (collectively, the \"Index Entities\") are members of a \"group\" for purposes of Section 13(d) of the Exchange Act."}],"balance_after":0,"derivative":{"exercise_price":5.772,"exercise_date":"2015-03-18","expiration_date":"2017-03-18","underlying":"Common Shares","underlying_shares":202634},"source":{"system":"sec-edgar","filing":"0001140361-16-089639","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000114036116089639/doc1.xml","form_type":"4"}},{"id":4521798,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":35600,"kind":"person","name":"De Rubertis Francesco","position":1,"cik":"0001601521","reported_name":"De Rubertis Francesco","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-14T19:22:20.000Z","date":"2016-12-12","kind":"other","acquired":true,"shares":202634,"price":5.772,"value":1169603.448,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Composed of 35,376 common shares acquired by Index Ventures III (Jersey), L.P., 71,862 common shares acquired by Index Ventures III (Delaware), L.P., 1,280 common shares acquired by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 48,790 common shares acquired by Index Ventures IV (Jersey), L.P., 4,631 common shares acquired by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 38,584 common shares acquired by Index Ventures V (Jersey), L.P., 313 common shares acquired by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 1,798 common shares acquired by Yucca (Jersey) SLP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Composed of 813,095 common shares held by Index Ventures III (Jersey), L.P., 1,651,714 common shares held by Index Ventures III (Delaware), L.P., 29,424 common shares held by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 1,129,474 common shares held by Index Ventures IV (Jersey), L.P., 107,210 common shares held by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 893,199 common shares held by Index Ventures V (Jersey), L.P., 7,238 common shares held by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 59,552 common shares held by Yucca (Jersey) SLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Index Venture Associates III Limited is the general partner of Index Ventures III (Jersey), L.P., Index Ventures III (Delaware), L.P., and Index Ventures III Parallel Entrepreneur Fund (Jersey)L.P. Yucca (Jersey) SLP is the Administrator of the Index Co-Investment Scheme acting through Elian Employee Benefit Services Limited. Index Venture Associates IV Limited is the general partner of Index Ventures IV (Jersey) L.P. and Index Ventures IV Parallel Entrepreneur Fund (Jersey) L.P. Index Venture Associates V Limited is the general partner of Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P. and Index Ventures V (Jersey), L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Composed of 813,095 common shares held by Index Ventures III (Jersey), L.P., 1,651,714 common shares held by Index Ventures III (Delaware), L.P., 29,424 common shares held by Index Ventures III Parallel Entrepreneur Fund (Jersey), L.P., 1,129,474 common shares held by Index Ventures IV (Jersey), L.P., 107,210 common shares held by Index Ventures IV Parallel Entrepreneur Fund (Jersey), L.P., 893,199 common shares held by Index Ventures V (Jersey), L.P., 7,238 common shares held by Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P., and 59,552 common shares held by Yucca (Jersey) SLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Michele Ollier, Director of the Issuer, is a partner of Medicxi Ventures (Jersey) Limited Succursale de Geneve which provides sub-advisory services to the foregoing funds and Dr. Ollier disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interest therein. Francesco De Rubertis, Director of the Issuer, is a partner of Medicxi Ventures (UK) LLP which provides sub-advisory services to the foregoing funds and Dr. De Rubertis disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein. Index Venture Associates III Limited, Index Venture Associates IV Limited, Index Venture Associates V Limited and Yucca (Jersey) SLP (collectively, the \"Index Entities\") are members of a \"group\" for purposes of Section 13(d) of the Exchange Act."}],"balance_after":4690906,"source":{"system":"sec-edgar","filing":"0001140361-16-089639","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000114036116089639/doc1.xml","form_type":"4"}}]}